Verici Dx plc (LON:VRCI – Get Free Report)’s stock price was down 2.7% during mid-day trading on Wednesday . The company traded as low as GBX 9 ($0.11) and last traded at GBX 9 ($0.11). Approximately 2,253,886 shares were traded during mid-day trading, an increase of 528% from the average daily volume of 358,724 shares. The stock had previously closed at GBX 9.25 ($0.12).
Verici Dx Stock Performance
The company has a debt-to-equity ratio of 9.28, a current ratio of 2.58 and a quick ratio of 8.49. The stock has a market capitalization of £22.43 million, a price-to-earnings ratio of -185.00 and a beta of 1.55. The business has a 50 day simple moving average of GBX 9.75 and a 200-day simple moving average of GBX 8.88.
Verici Dx Company Profile
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Featured Stories
- Five stocks we like better than Verici Dx
- What Does a Stock Split Mean?
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What is the Hang Seng index?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- How to Use the MarketBeat Stock Split Calculator
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
